Navigation Links
High Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer Following External Beam Radiation Therapy Investigated in Phase III Clinical Study
Date:9/11/2008

CHARLOTTE, N.C., Sept. 11 /PRNewswire/ -- In a new study, men with locally recurrent prostate cancer may be able to receive a promising investigational ultrasound treatment option.

A Phase III clinical trial at Specialists in Urology, located in North Naples, FL, is investigating the safety and efficacy of High Intensity Focused Ultrasound (HIFU) for the treatment of locally recurrent prostate cancer following failed external beam radiation therapy (EBRT). HIFU is a minimally invasive procedure that uses ultrasound energy to destroy cancerous tissue with focused sound waves.

The lead investigator of this trial site is Dr. Nicholas Franco. This is one of several trial sites in the nation approved by the Food and Drug Administration to participate in the trial, which will begin enrolling patients in September.

HIFU is intended to eliminate cancer by elevating tissue temperatures to more than 195 degrees Fahrenheit in a matter of seconds. The Sonablate(R) 500, the therapeutic ultrasound device, which will be used in the study, is designed to destroy the entire gland in one procedure without causing damage to tissue around the prostate.

Eligible participants for the trial must be between the ages of 40 and 80, have biopsy confirmed local recurrence two or more years following EBRT, confined prostate cancer with a prostate specific antigen (PSA) greater than or equal to .5 ng/mL and less than or equal to 10 ng/mL and a Gleason score of less than or equal to seven.

For more information about enrolling in the HIFU trial, call 1-877-874-4389, or visit http://www.ProstateCancerRecurrentTrial.org.

This investigational treatment is performed on an outpatient basis. Potential risks of the treatment include frequency, urgency, mild discomfort or discharge in urinary stream. Less common side effects may also include urinary stricture, retention, incontinence, impotence and rectal fistula.

Prostate cancer is the most common type of non-skin cancer in American men and the second leading cause of cancer deaths in men. The American Cancer Society estimates that there were about 234,460 new cases of prostate cancer in the U.S. in 2006 and that 27,350 men die annually from the disease.


'/>"/>
SOURCE USHIFU
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Nations Foremost Health Care Leaders Kick Off Summit Focused on Zero-Tolerance Approach to Hospital-Acquired Infections
2. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
3. ACORNs Oncology-focused Contract Research Organization Exceeds Projections
4. Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
5. Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer
6. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
7. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
8. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
9. Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
10. Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease
11. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):